A detailed history of Capital International Sarl transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Capital International Sarl holds 135,073 shares of ALNY stock, worth $33.2 Million. This represents 1.0% of its overall portfolio holdings.

Number of Shares
135,073
Previous 109,815 23.0%
Holding current value
$33.2 Million
Previous $26.7 Million 39.24%
% of portfolio
1.0%
Previous 0.85%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$233.81 - $287.01 $5.91 Million - $7.25 Million
25,258 Added 23.0%
135,073 $37.2 Million
Q2 2024

Aug 13, 2024

BUY
$143.31 - $247.0 $5.26 Million - $9.07 Million
36,706 Added 50.21%
109,815 $26.7 Million
Q1 2024

May 14, 2024

SELL
$146.51 - $198.2 $2.09 Million - $2.82 Million
-14,248 Reduced 16.31%
73,109 $10.9 Million
Q4 2023

Feb 13, 2024

BUY
$151.41 - $196.57 $65,863 - $85,507
435 Added 0.5%
87,357 $16.7 Million
Q3 2023

Nov 13, 2023

BUY
$170.77 - $211.65 $430,852 - $533,992
2,523 Added 2.99%
86,922 $15.4 Million
Q2 2023

Aug 11, 2023

BUY
$185.01 - $212.05 $1.35 Million - $1.55 Million
7,309 Added 9.48%
84,399 $16 Million
Q1 2023

May 15, 2023

BUY
$182.66 - $235.53 $1.87 Million - $2.41 Million
10,214 Added 15.27%
77,090 $15.4 Million
Q4 2022

Feb 14, 2023

BUY
$185.53 - $241.31 $4.18 Million - $5.44 Million
22,551 Added 50.88%
66,876 $15.9 Million
Q3 2022

Nov 14, 2022

BUY
$138.54 - $232.0 $1.86 Million - $3.12 Million
13,456 Added 43.59%
44,325 $8.87 Million
Q2 2022

Aug 15, 2022

BUY
$120.42 - $169.29 $2.11 Million - $2.97 Million
17,554 Added 131.84%
30,869 $4.5 Million
Q1 2022

May 16, 2022

BUY
$127.18 - $173.91 $1.69 Million - $2.32 Million
13,315 New
13,315 $2.17 Million

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $30.2B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Capital International Sarl Portfolio

Follow Capital International Sarl and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International Sarl, based on Form 13F filings with the SEC.

News

Stay updated on Capital International Sarl with notifications on news.